GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BFRI · Sep 30, 2024

Biofrontera Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001493152-24-045220General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-13.40% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

1.30% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

72.41% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-55.04% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

7.42% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

3.20% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20244/7 normalizedLevel 3 Mar 31, 20254/7 normalizedLevel 3 Jun 30, 20255/7 normalizedLevel 3 Sep 30, 20256/7 normalizedLevel 3 Dec 31, 20257/7 normalizedLevel 3 Mar 31, 20267/7 normalizedLevel 3 Jun 30, 20267/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: -0.61%
Current: 0.00%
Delta: 0.61%

Cash Generation Increased

Previous: -60.21%
Current: -13.40%
Delta: 46.81%

Growth Decreased

Previous: 34.05%
Current: 1.30%
Delta: -32.74%

Inventory Pressure Increased

Previous: 50.34%
Current: 72.41%
Delta: 22.08%

Profitability Increased

Previous: -64.69%
Current: -55.04%
Delta: 9.65%

R And D Intensity Decreased

Previous: 7.92%
Current: 7.42%
Delta: -0.50%

Sbc Intensity Increased

Previous: 2.60%
Current: 3.20%
Delta: 0.59%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · BFRI Fundamental State →Has State · Biofrontera Inc. →Transitioned To · BFRI Fundamental State →Transitioned To · BFRI CAPEX_INTENSITY_INCREASED →Transitioned To · BFRI CASH_GENERATION_INCREASED →Transitioned To · BFRI GROWTH_DECREASED →Transitioned To · BFRI INVENTORY_PRESSURE_INCREASED →Transitioned To · BFRI PROFITABILITY_INCREASED →Transitioned To · BFRI R_AND_D_INTENSITY_DECREASED →Transitioned To · BFRI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.